Instrument Inactif

Autres langues GOLD SWAP OTC Bulletin Board

Actions

GDSW

US38074W1009

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

10/07	Les plus fortes baisses à la mi-séance	MT
10/07	Silo Pharma lance un placement privé pour lever jusqu'à 11,7 millions de dollars	MT

Autres langues

14/07	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
10/07	Top Midday Decliners
10/07	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million
10/07	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09/07	Silo Pharma, Inc. announced that it has received $4.000015 million in funding
07/07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
29/06	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
29/06	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request
23/06	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial
23/06	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months
23/06	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
18/06	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement
18/06	Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
04/06	Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split
14/05	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.
14/05	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
07/05	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
29/04	Silo Pharma's PTSD program advances as FDA fast-tracks psychedelic therapies for PTSD
29/04	Silo Pharma : PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
29/04	Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
29/04	Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
22/04	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
22/04	Silo Pharma, Inc. acquired Qwikagents.com, Qikagents.ai, and Qwikagents.co from Many Ads Inc. for $0.7 million.
20/04	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics